Department of Oral and Maxillofacial Surgery/Plastic Surgery, University Hospital Mainz, Mainz, Germany.
Clin Oral Implants Res. 2012 Sep;23(9):1112-7. doi: 10.1111/j.1600-0501.2011.02275.x.
The aim of this study was to evaluate the extent and quality of new bone 6 months after sinus lift with biphasic micro- and macroporous calcium phosphate combined with fibrin sealant (MBCP-FS) and the 1-year implant success rate in the augmented site.
MBCP-FS was applied to one sinus in 96 subjects requiring augmentation for delayed dental implant placement. In subjects who required bilateral lifts (N = 33), the MBCP-FS sinus was randomly selected; the contralateral sinus was grafted with autologous bone (mixed with Bio-Oss when harvested bone volume was insufficient. Panoramic views were taken periodically prior to and up to 18 months post-lift. Histomorphometric analysis was conducted on biopsies taken during implant placement 6 months after augmentation. Implant functionality and prosthesis success were assessed clinically 1 year after implant placement.
In MBCP-FS sinuses, 20.6 ± 8.5% new, mainly lamellar bone was observed. Implants were placed as planned in 78/85 evaluable subjects (91.8%) 6 months after sinus lift. Graft heights remained stable 1 year after placement; 94.7% (142/150) of implants were functional. The amount and quality of new bone and implant success rates with MBCP-FS were similar to autologous bone graft (mixed with Bio-Oss in 30/31 evaluable subjects). MBCP-FS was safe and well-tolerated.
MBCP-FS is safe and effective in sinus floor elevation for dental implant placement, supporting bone regeneration and with high 1-year implant success rates similar to autologous bone mixed with Bio-Oss.
本研究旨在评估双相微/大孔磷酸钙与纤维蛋白密封剂(MBCP-FS)联合应用于鼻窦提升 6 个月后新骨的量和质量,以及增强部位植入物的 1 年成功率。
将 MBCP-FS 应用于 96 名需要延迟牙种植体植入的患者的一个鼻窦中。在需要双侧提升的患者(N=33)中,随机选择 MBCP-FS 鼻窦;对侧鼻窦用自体骨(当采集的骨量不足时与 Bio-Oss 混合)进行移植。在提升前和提升后 18 个月定期拍摄全景图。在增强后 6 个月植入物放置时进行活检的组织形态计量学分析。植入物放置 1 年后,通过临床评估植入物的功能和修复体的成功率。
在 MBCP-FS 鼻窦中,观察到 20.6±8.5%的新骨,主要为板层骨。在鼻窦提升后 6 个月,78/85 名可评估患者(91.8%)按计划植入了植入物。植入物放置 1 年后,移植物高度保持稳定;94.7%(142/150)的植入物功能正常。MBCP-FS 的新骨量和质量以及植入物成功率与自体骨(在 30/31 名可评估患者中与 Bio-Oss 混合)相似。MBCP-FS 安全且耐受性良好。
MBCP-FS 安全有效,可用于牙种植体植入的鼻窦提升,支持骨再生,植入物 1 年成功率高,与自体骨与 Bio-Oss 混合的成功率相似。